Skip To Main Content
Makiko Kobarad on Muck Rack

Makiko Kobarad

As seen in: The Oncologist
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Makiko

Contact Makiko, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

A Prospective Trial Evaluating the Safety of a Shortened Infusion of Ramucirumab in Patients with Gastrointestinal Cancer

|
By Makiko Kobarad, Naoya Hashimoto, Seiichiro Mitani, Hiroya Taniguchi
| The Oncologist Verified
Advertisement Advertisement Naoya Hashimotoa, Seiichiro Mitanib, Hiroya Taniguchi (h.taniguchi{at}aichi-cc.jp)*,b, Yukiya Naritab, Kyoko Katob, Toshiki Masuishib, Shigenori Kadowakib, Sachiyo Onishic, Masahiro Tajikac, Shinji Takahashia, Kazuhiro Shimomuraa, Chihoko Takahatad, Eri Hottad, Makiko Kobarad and Kei Murob a Department of Pharmacy, Aichi Cancer Center Hospital, Nagoya, Japan b Department of Clinical Oncology, Aichi Cancer Center Hospital, Nagoya, Japan c Department of Endoscopy,...
Open in Who Shared Issue with article?

A Prospective Trial Evaluating the Safety of a Shortened Infusion of Ramucirumab in Patients with Gastrointestinal Cancer

|
By Seiichiro Mitani, Hiroya Taniguchi, Makiko Kobarad, Naoya Hashimoto
| The Oncologist Verified
Ramucirumab is usually administered over 60 minutes, during which it is unlikely to cause infusion‐related reactions (IRRs). This prospective study evaluated the safety of a shortened infusion of ramucirumab. Patients who received their first dose of ramucirumab in a 60‐minute infusion without developing IRRs were eligible and received their second ramucirumab dose for 20 minutes.
Open in Who Shared Issue with article?
See all 2 articles